Somatic TET2 mutations were first reported as present in ~15% of myeloid cancers, with the loss of function mutations in TET2 accounting for approximately 10% of newly onset AML, 50% of CMML, and approximately one‐third of all mutations in myelodysplastic syndromes.92, 93. Here, TET2 is linked to myelodysplastic syndrome.